Literature DB >> 25007789

Unraveling the PAF-AH/Lp-PLA2 controversy.

Diana M Stafforini1, Guy A Zimmerman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25007789      PMCID： PMC4617349          DOI： 10.1194/jlr.E052886

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  43 in total

1.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

2.  Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.

Authors:  Hiroyuki Daida; Takayuki Iwase; Shigeru Yagi; Hidekazu Ando; Hiromu Nakajima
Journal:  Circ J       Date:  2013-02-23       Impact factor: 2.993

3.  Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.

Authors:  Michelle L O'Donoghue; Eugene Braunwald; Harvey D White; Patrick Serruys; Ph Gabriel Steg; Judith Hochman; Aldo P Maggioni; Christoph Bode; Douglas Weaver; Joel L Johnson; Greg Cicconetti; Mary Ann Lukas; Elizabeth Tarka; Christopher P Cannon
Journal:  Am Heart J       Date:  2011-09-15       Impact factor: 4.749

Review 4.  Phospholipase A2s: developing drug targets for atherosclerosis.

Authors:  Keith Suckling
Journal:  Atherosclerosis       Date:  2010-03-16       Impact factor: 5.162

5.  Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.

Authors:  Sung Kee Ryu; Ziad Mallat; Joelle Benessiano; Alain Tedgui; Anders G Olsson; Weihang Bao; Gregory G Schwartz; Sotirios Tsimikas
Journal:  Circulation       Date:  2012-01-09       Impact factor: 29.690

6.  Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Robert L Wolfert; Wolfgang Koenig
Journal:  Clin Chem       Date:  2012-03-14       Impact factor: 8.327

7.  The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.

Authors:  Miao-miao Hu; Jie Zhang; Wen-yi Wang; Wen-yu Wu; Yan-ling Ma; Wei-hai Chen; Yi-ping Wang
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

8.  Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study).

Authors:  Marcus E Kleber; Robert L Wolfert; Graciela Delgado De Moissl; Tanja B Grammer; Simone Dietz; Bernhard R Winkelmann; Bernhard O Boehm; Winfried März
Journal:  Clin Lab       Date:  2011       Impact factor: 1.138

Review 9.  Generation of membrane diversity by lysophospholipid acyltransferases.

Authors:  Hideo Shindou; Daisuke Hishikawa; Takeshi Harayama; Miki Eto; Takao Shimizu
Journal:  J Biochem       Date:  2013-05-21       Impact factor: 3.387

10.  Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.

Authors:  Wen-yi Wang; Jie Zhang; Wen-yu Wu; Jie Li; Yan-ling Ma; Wei-hai Chen; Hong Yan; Kai Wang; Wen-wei Xu; Jian-hua Shen; Yi-ping Wang
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240
View more
  11 in total

1.  Introduction to Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease.

Authors:  Edward A Dennis
Journal:  J Lipid Res       Date:  2015-06-01       Impact factor: 5.922

2.  Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF.

Authors:  Vyala Hanumanthareddy Chaithra; Shancy Petsel Jacob; Chikkamenahalli Lakshminarayana Lakshmikanth; Mosale Seetharam Sumanth; Kandahalli Venkataranganayaka Abhilasha; Chu-Huang Chen; Anita Thyagarajan; Ravi P Sahu; Jeffery Bryant Travers; Thomas M McIntyre; Kempaiah Kemparaju; Gopal Kedihithlu Marathe
Journal:  J Lipid Res       Date:  2018-08-23       Impact factor: 5.922

3.  Hydrolysis of Phosphatidylcholine-Isoprostanes (PtdCho-IP) by Peripheral Human Group IIA, V and X Secretory Phospholipases A2 (sPLA2).

Authors:  Arnis Kuksis; Waldemar Pruzanski
Journal:  Lipids       Date:  2017-05-20       Impact factor: 1.880

4.  SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.

Authors:  L G Moise; D S Marta; A Raşcu; E Moldoveanu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jan-Mar       Impact factor: 0.877

Review 5.  Phospholipid signaling in innate immune cells.

Authors:  Valerie B O'Donnell; Jamie Rossjohn; Michael Jo Wakelam
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

6.  The role of Lp-PLA2 and biochemistry parameters as potential biomarkers of coronary artery disease in Asian South-Indians: a case-control study.

Authors:  Sai Giridhar Sairam; Srikanth Sola; Asha Barooah; Sai Kiran Javvaji; Jiten Jaipuria; Vijayalakshmi Venkateshan; Janardhana Chelli; Carani Balaraman Sanjeevi
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 7.  Bioactive Carbohydrates and Peptides in Foods: An Overview of Sources, Downstream Processing Steps and Associated Bioactivities.

Authors:  Maria Hayes; Brijesh K Tiwari
Journal:  Int J Mol Sci       Date:  2015-09-17       Impact factor: 5.923

Review 8.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

Review 9.  Inflammation, not Cholesterol, Is a Cause of Chronic Disease.

Authors:  Alexandros Tsoupras; Ronan Lordan; Ioannis Zabetakis
Journal:  Nutrients       Date:  2018-05-12       Impact factor: 5.717

10.  Metabolic Dysregulation of the Lysophospholipid/Autotaxin Axis in the Chromosome 9p21 Gene SNP rs10757274.

Authors:  Sven W Meckelmann; Jade I Hawksworth; Daniel White; Robert Andrews; Patricia Rodrigues; Anne O'Connor; Jorge Alvarez-Jarreta; Victoria J Tyrrell; Christine Hinz; You Zhou; Julie Williams; Maceler Aldrovandi; William J Watkins; Adam J Engler; Valentina Lo Sardo; David A Slatter; Stuart M Allen; Jay Acharya; Jacquie Mitchell; Jackie Cooper; Junken Aoki; Kuniyuki Kano; Steve E Humphries; Valerie B O'Donnell
Journal:  Circ Genom Precis Med       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.